vs
Side-by-side financial comparison of Sotera Health Co (SHC) and VIEMED HEALTHCARE, INC. (VMD). Click either name above to swap in a different company.
Sotera Health Co is the larger business by last-quarter revenue ($303.4M vs $76.2M, roughly 4.0× VIEMED HEALTHCARE, INC.). Sotera Health Co runs the higher net margin — 11.5% vs 7.4%, a 4.1% gap on every dollar of revenue. On growth, VIEMED HEALTHCARE, INC. posted the faster year-over-year revenue change (25.5% vs 4.6%). Sotera Health Co produced more free cash flow last quarter ($52.4M vs $9.7M). Over the past eight quarters, VIEMED HEALTHCARE, INC.'s revenue compounded faster (22.7% CAGR vs 10.6%).
Sotera Health Co is a global provider of end-to-end medical safety solutions. It offers sterilization services, analytical laboratory testing, and regulatory advisory support for medical device manufacturers, pharmaceutical firms, and food and consumer product companies, helping clients meet industry standards and ensure product safety for end users worldwide.
Viemed Healthcare, Inc. is a medical technology firm specializing in respiratory care solutions. It develops, manufactures and distributes portable ventilators, respiratory therapy devices and related support services, catering to acute care, post-acute care and home care segments across North America, Europe and key Asia-Pacific markets for patients with respiratory conditions.
SHC vs VMD — Head-to-Head
Income Statement — Q4 2025 vs Q4 2025
| Metric | | |
|---|---|---|
| Revenue | $303.4M | $76.2M |
| Net Profit | $34.8M | $5.6M |
| Gross Margin | 54.7% | 57.9% |
| Operating Margin | 23.2% | 11.0% |
| Net Margin | 11.5% | 7.4% |
| Revenue YoY | 4.6% | 25.5% |
| Net Profit YoY | 182.8% | 30.7% |
| EPS (diluted) | $0.12 | $0.14 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $303.4M | $76.2M | ||
| Q3 25 | $311.3M | $71.9M | ||
| Q2 25 | $294.3M | $63.1M | ||
| Q1 25 | $254.5M | $59.1M | ||
| Q4 24 | $290.2M | $60.7M | ||
| Q3 24 | $285.5M | $58.0M | ||
| Q2 24 | $276.6M | $55.0M | ||
| Q1 24 | $248.2M | $50.6M |
| Q4 25 | $34.8M | $5.6M | ||
| Q3 25 | $48.4M | $3.5M | ||
| Q2 25 | $8.0M | $3.2M | ||
| Q1 25 | $-13.3M | $2.6M | ||
| Q4 24 | $12.3M | $4.3M | ||
| Q3 24 | $17.0M | $3.9M | ||
| Q2 24 | $8.8M | $1.5M | ||
| Q1 24 | $6.3M | $1.6M |
| Q4 25 | 54.7% | 57.9% | ||
| Q3 25 | 57.0% | 57.5% | ||
| Q2 25 | 56.6% | 58.3% | ||
| Q1 25 | 53.2% | 56.3% | ||
| Q4 24 | 56.6% | 59.5% | ||
| Q3 24 | 55.4% | 59.3% | ||
| Q2 24 | 55.2% | 59.8% | ||
| Q1 24 | 51.2% | 58.9% |
| Q4 25 | 23.2% | 11.0% | ||
| Q3 25 | 23.4% | 7.8% | ||
| Q2 25 | 6.4% | 8.1% | ||
| Q1 25 | -5.8% | 6.5% | ||
| Q4 24 | 30.0% | 10.6% | ||
| Q3 24 | 28.2% | 9.7% | ||
| Q2 24 | 27.8% | 6.6% | ||
| Q1 24 | 21.4% | 4.4% |
| Q4 25 | 11.5% | 7.4% | ||
| Q3 25 | 15.5% | 4.9% | ||
| Q2 25 | 2.7% | 5.0% | ||
| Q1 25 | -5.2% | 4.4% | ||
| Q4 24 | 4.2% | 7.1% | ||
| Q3 24 | 6.0% | 6.7% | ||
| Q2 24 | 3.2% | 2.7% | ||
| Q1 24 | 2.5% | 3.2% |
| Q4 25 | $0.12 | $0.14 | ||
| Q3 25 | $0.17 | $0.09 | ||
| Q2 25 | $0.03 | $0.08 | ||
| Q1 25 | $-0.05 | $0.06 | ||
| Q4 24 | $0.05 | $0.10 | ||
| Q3 24 | $0.06 | $0.10 | ||
| Q2 24 | $0.03 | $0.04 | ||
| Q1 24 | $0.02 | $0.04 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $344.6M | $13.5M |
| Total DebtLower is stronger | $2.1B | — |
| Stockholders' EquityBook value | $606.0M | $141.5M |
| Total Assets | $3.3B | $199.2M |
| Debt / EquityLower = less leverage | 3.53× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $344.6M | $13.5M | ||
| Q3 25 | $299.2M | $11.1M | ||
| Q2 25 | $332.4M | $20.0M | ||
| Q1 25 | $304.4M | $10.2M | ||
| Q4 24 | $277.2M | $17.5M | ||
| Q3 24 | $306.7M | $11.3M | ||
| Q2 24 | $246.1M | $8.8M | ||
| Q1 24 | $261.1M | $7.3M |
| Q4 25 | $2.1B | — | ||
| Q3 25 | $2.1B | — | ||
| Q2 25 | $2.2B | — | ||
| Q1 25 | $2.2B | — | ||
| Q4 24 | $2.2B | — | ||
| Q3 24 | $2.2B | — | ||
| Q2 24 | $2.2B | — | ||
| Q1 24 | $2.2B | — |
| Q4 25 | $606.0M | $141.5M | ||
| Q3 25 | $550.5M | $133.6M | ||
| Q2 25 | $511.3M | $139.7M | ||
| Q1 25 | $414.1M | $134.8M | ||
| Q4 24 | $404.9M | $131.4M | ||
| Q3 24 | $470.2M | $125.0M | ||
| Q2 24 | $422.8M | $119.4M | ||
| Q1 24 | $429.4M | $116.3M |
| Q4 25 | $3.3B | $199.2M | ||
| Q3 25 | $3.2B | $202.4M | ||
| Q2 25 | $3.2B | $184.6M | ||
| Q1 25 | $3.1B | $178.1M | ||
| Q4 24 | $3.1B | $177.1M | ||
| Q3 24 | $3.1B | $169.5M | ||
| Q2 24 | $3.1B | $163.9M | ||
| Q1 24 | $3.1B | $154.9M |
| Q4 25 | 3.53× | — | ||
| Q3 25 | 3.89× | — | ||
| Q2 25 | 4.34× | — | ||
| Q1 25 | 5.36× | — | ||
| Q4 24 | 5.49× | — | ||
| Q3 24 | 4.73× | — | ||
| Q2 24 | 5.26× | — | ||
| Q1 24 | 5.19× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $103.1M | $18.4M |
| Free Cash FlowOCF − Capex | $52.4M | $9.7M |
| FCF MarginFCF / Revenue | 17.3% | 12.7% |
| Capex IntensityCapex / Revenue | 16.7% | 11.5% |
| Cash ConversionOCF / Net Profit | 2.96× | 3.27× |
| TTM Free Cash FlowTrailing 4 quarters | $149.2M | $11.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $103.1M | $18.4M | ||
| Q3 25 | $71.2M | $18.4M | ||
| Q2 25 | $57.4M | $12.3M | ||
| Q1 25 | $55.5M | $2.9M | ||
| Q4 24 | $55.7M | $15.0M | ||
| Q3 24 | $97.5M | $12.7M | ||
| Q2 24 | $61.3M | $10.2M | ||
| Q1 24 | $9.7M | $1.2M |
| Q4 25 | $52.4M | $9.7M | ||
| Q3 25 | $35.0M | $10.7M | ||
| Q2 25 | $26.2M | $4.1M | ||
| Q1 25 | $35.6M | $-12.6M | ||
| Q4 24 | $-10.2M | $3.2M | ||
| Q3 24 | $61.1M | $1.7M | ||
| Q2 24 | $19.4M | $1.2M | ||
| Q1 24 | $-25.2M | $-4.8M |
| Q4 25 | 17.3% | 12.7% | ||
| Q3 25 | 11.2% | 14.9% | ||
| Q2 25 | 8.9% | 6.5% | ||
| Q1 25 | 14.0% | -21.4% | ||
| Q4 24 | -3.5% | 5.2% | ||
| Q3 24 | 21.4% | 3.0% | ||
| Q2 24 | 7.0% | 2.3% | ||
| Q1 24 | -10.2% | -9.5% |
| Q4 25 | 16.7% | 11.5% | ||
| Q3 25 | 11.6% | 10.6% | ||
| Q2 25 | 10.6% | 12.9% | ||
| Q1 25 | 7.8% | 26.2% | ||
| Q4 24 | 22.7% | 19.5% | ||
| Q3 24 | 12.7% | 19.0% | ||
| Q2 24 | 15.2% | 16.3% | ||
| Q1 24 | 14.1% | 11.9% |
| Q4 25 | 2.96× | 3.27× | ||
| Q3 25 | 1.47× | 5.23× | ||
| Q2 25 | 7.21× | 3.88× | ||
| Q1 25 | — | 1.09× | ||
| Q4 24 | 4.52× | 3.47× | ||
| Q3 24 | 5.73× | 3.29× | ||
| Q2 24 | 7.00× | 6.94× | ||
| Q1 24 | 1.53× | 0.73× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
SHC
| Transferred At Point In Time | $198.4M | 65% |
| Nelson Labs | $55.2M | 18% |
| Nordion | $49.8M | 16% |
VMD
Segment breakdown not available.
